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Background: Recurrent adverse cardiovascular events (MACE) are a challenge for
interventional cardiology. In the PROSPECT study, 697 patients with acute coronary
syndromes underwent coronary angiography and intravascular ultrasound for lesion
characterization. We aimed at a biomarker based characterization of patients prone for
MACE and related the results to lesion characteristics.
Methods: We measured a large set of vascular and cardiovascular risk related biomarkers
including hsTnI, GDF-15, PLGF, sFLT-1, homocysteine, NGAL, hsCRP, LP(a), Cystatin
C, ApoA1, ApoB and beta-2-microglobulin in baseline, day 30 and day 180 blood
samples of the PROSPECT study and analysed the relation to outcome. Markers for
multivariate analysis were sFLT-1, Cystatin C and beta-2-microglobulin selected by p
0.1 in bivariate analysis. The biomarkers were tested using either commercially
available or prototype ARCHITECT(R) assays.Three years MACE (death from cardiac
causes, cardiac arrest, myocardial infarction, or rehospitalization due to unstable or
progressive angina) were related to a non-culprit lesion of the index event (NCMACE).
Results: Median [IQR] sFLT-1 levels were higher in patients without NCMACE 735.5
[334.2, 4024.4] versus 479.2 [244.9, 1362.0] pg/mL (p0.03); Cystatin C was slightly
higher in patients with NCMACE 0.77 [0.68, 0.90] versus 0.72 [0.64, 0.84]mg/L
(p0.07) and so was the beta-2-microglobulin 1.99 [1.61, 2.31] versus 1.79 [1.52, 2.12]
mg/L (p0.02). At 6 months sFLT-1 decreased and the difference disappeared 212.4
[183.7, 252.1] versus 220.4 [191.7, 248.8], while the latter markers increased slightly and
remained significant. Patients with any MACE in the follow up had higher values of
GDF-15 at baseline 893.0 [716.3, 1254.3] versus 799.9 [616.9, 1130.1] pg/mL (p0.02),
also higher Cystatin C and beta-2-microglobulin and lower HDL and ApoA1. In the
multivariate analysis only insulin dependent diabetes (IDDM; HR 3.43 [ 1.38, 8.58]) and
history of AP remained significant predictors of NCMACE.
Conclusions: Patients with non-culprit lesions MACE in the long-term follow up have
specific biomarker profiles. This may impact for the personalization of intensified
anti-thrombotic treatment in the future.
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Background: Efficacy of primary percutaneous coronary intervention (pPCI) for acute
myocardial infarction has been established by abundant evidences, however, impact of
restenosis after pPCI in cardiac function or long-term prognosis remains unclear.
Methods: We investigated 339 STEMI patients who had undergone pPCI with bare
metal stent between May 2004 and June 2009 followed by rest (acute phasewithin 2
weeks) /exercise stress (chronic phase3 months after onset) 99m-Tc-Tetrofosmin
scintigraphy (TcTF) and follow-up coronary angiography (CAG). According to the result
of follow-up CAG, they were divided into three groups (A: no in-stent restenosis (ISR),
n228; B: ISR without occlusion, n86; C: ISR with occlusion, n25). Those with
symptomatic stent thrombosis before F/U CAG were excluded. Perfusion defect score
(DS), left ventricular ejection fraction (LVEF) and myocardial ischemia were evaluated
by TcTF. Re-hospitalization due to congestive heart failure, new onset acute coronary
syndrome (ACS) (except due to restenosis) and cardiac death were investigated as clinical
events.
Results: In acute phase, there were no significant differences in perfusion DS and LVEF
among three groups. However, in chronic phase, group C showed significantly lower
LVEF, greater perfusion DS than other two groups. Furthermore, during follow-up period
(3-8 years) prevalence of heart failure requiring rehospitalization and new onset ACS was
significantly higher in group C.
(A) No
ISR
(B) ISR
without
occlusion
(C) ISR
with
occlusion A vs.
B
A vs.
C
B vs.
CN228 N86 N25
Perfusion DS (acute) 18.1 18.6 20.6 N.S. N.S. N.S.
EF (%) (acute) 45.8 47.7 44.8 N.S. N.S. N.S.
Perfusion DS(chronic) 15.8 17.0 21.8 N.S. 0.05 0.05
EF (%) (chronic) 54.4 52.8 47.6 N.S. 0.05 0.05
CHF hospitalization (%) 8.4 9.4 40.0 N.S.0.001 0.001
Total Events (%) 14.0 14.0 56.0 N.S.0.001 0.001
Conclusions: Silent occlusion after pPCI is associated with deteriorated cardiac function,
progression of chronic heart failure and rehospitalization. However, such observations
were not observed in non-occlusive ISR. Coronary artery patency, but not the grade of
stenosis is an important predictor of prognosis in STEMI treated by successful pPCI.
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Background: There are still debates regarding the benefits of adjunctive thrombectomy
devices in ST-elevation myocardial infarction (STEMI) patients undergoing primary
percutaneous coronary intervention (PCI). The objective of this study was to perform an
updated meta-analysis of published clinical trials conducted with adjunctive devices to
prevent distal embolization in the setting of primary PCI.
Methods: We searched MEDLINE, EMBASE, Cochrane databases for randomized,
case-control, and cohort studies on adjunctive devices to prevent distal embolization in
STEMI from January 2002 to May 2012.
Results: A total of 22 trials with 7,229 patients were included. The use of adjunctive
thrombectomy devices was associated with significantly higher incidence of postproce-
dural ST-segment resolution (odds ratio [OR] 2.04, 95% confidence interval [CI] 1.50 to
2.78, p0.001) and myocardial blush grade 3 (OR 2.26, 95% CI 1.34 to 3.81, p0.002).
There were no significant differences in the rates of final Thrombolysis in Myocardial
Infarction grade 3 flow (OR 1.19, 95% CI 0.88 to 1.62, p0.25) and incidence of distal
embolization (OR 0.61, 95% CI 0.37 to 1.02, p0.06). Thrombectomy devices were
associated with a significant reduction in MACE (OR 0.81, 95% CI 0.68 to 0.98, p0.03)
with no difference in mortality (OR 0.97, 95% CI 0.73 to 1.29, p0.81).
Conclusions: Use of adjunctive thrombectomy devices is associated with better myo-
cardial perfusion and trend toward lesser distal embolization after primary PCI without
significant improvement in mortality.
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Small Versus Large Culprit Vessel Size In Primary Percutaneous Coronary
Intervention For ST Elevation Myocardial Infarction: Incidence, Clinical
Characteristics And Outcome Differences.
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Background: The impact of culprit vessel size on outcome in primary percutaneous
coronary intervention (PPCI) is not well studied. We aimed to analyse the incidence,
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clinical characteristics and outcome for patients undergoing small versus large culprit
vessel PPCI in our unit.
Methods: We included all patients who underwent PPCI in our unit between Sept 2009
and May 2011. They were divided into two groups according to the size of the largest
balloon or stent used in the culprit lesion.
Results: Of the 1132 patients who underwent PPCI in our unit during the study period,
we excluded 30 (2.7%) patients who did not have either a balloon or stent used in the
culprit lesion. Of the remaining 1102 patients, 569 (51.6%) had small (3 mm) vessel
PPCI and 533 (48.4%) had large (3 mm) vessel PPCI. Patients with small vessel PPCI
were significantly older, more likely to be female and have anterior STEMI with less use
of thrombectomy device, but with significantly higher drug eluting stent (DES) usage.
There was significantly higher in-hospital mortality (5.3% vs 2.8%, OR 1.9, 95% CI 1-3.6,
p 0.047), 30-day mortality (8.4% vs 3.6%,OR 2.5, 95% CI 1.4-4.3, p 0.0009) and 30-day
stent thrombosis (1.2% vs 0, p 0.02) in the small vessel PPCI group compared to large
vessel PPCI group. On binary logistic regression analysis of small vessel PPCI patients
(covariates used: female sex, Age 75 yrs, cardiogenic shock, diabetes, LAD PCI and
DES use), the positive predictors of 30-day mortality were age75 yrs (OR 6.1, 95% CI
2.9 to 12.5, p0.0001) and cardiogenic shock (OR 9.9, 95% CI 4.3-22.6, p0.0001) with
DES use (OR 0.4, 95% CI 0.2-0.8, p 0.01) being the only negative predictor of mortality.
N (%)
Small (<3 mm)
vessel
Large (> 3 mm)
vessel
p valueN 569 N 533
Age (meanSD,
range)
66.813.5, 25-96 62.913.1, 26-99 0.0001
Age  75 yrs 172 (30.2) 94 (17.6) 0.0001
Female 203 (35.7) 94 (17.6) 0.0001
Diabetes 68 (11.8) 63 (11.8) 1.0
Cardiogenic shock 42 (7.4) 42 (7.9) 0.73
Previous MI 65 (11.4) 69 (12.9) 0.46
Previous PCI 33 (5.8) 42 (7.9) 0.19
Previous CABG 11 (1.9) 16 (3) 0.33
LAD PCI 293 (51.5) 218 (40.9) 0.0005
Thrombectomy use 363 (63.8) 424 (79.5) 0.0001
Drug eluting stent use
(at least one)
363 (63.8) 289 (54.2) 0.001
Conclusions: In this large consecutive PPCI series from a single center, small culprit
vessel size was associated with significantly higher 30-day mortality, more than double
the mortality seen in patients with a large culprit vessel.
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Background: Elderly constitute an increasing proportion of all patients, who are
admitted for ACS to the hospital, but on the other hand increased age has been identified
as an important risk factor for death or recurrent MI in this subset. Furthermore elderly
patients are at higher risk for complications with interventional procedures, therefore the
overall benefit in such procedures, facing a limited life expectancy in elderly patients
anyway, still remains uncertain. The purpose of this study was to identify predictors of
longtime survival in either interventionally or conservatively treated elderly patients with
ACS in a large consecutive series of elderly ( 75 years).
Methods: Between 01/05 and 11/07 1001 patients  75 ys. were admitted with the
diagnosis of ACS in our hospital. Records were evaluated and patients were identified on
the basis of their discharge diagnosis. Adverse outcome, defined as the appearance of
death, myocardial infarction, complicated hospital stay, pneumonia and interventional
complications like bleeding, stroke and reinfarction etc. was evaluated. Using a multi-
variate regression analysis, factors which predicted long-time mortality were identified.
Results: Out of 1001 patients (mean age 815 Jahre, 512 (51.1% female), Killip-class
1,40,75, EF 4715%) 776 [77.5 %] were treated invasively; wherease 247 [22.5%]
were teated conservatively. Mean survival for conservatively treated NSTEMI patients
was 78953 vs. 123729 in the invasively treated patients, in the STEMI group survival
was 706128 for conservatively and 123844 days for interventionally treated patients
respectively (p0.001). As predictors of long term mortality we identified renal failure
((p0.001), insulin-treated Diabetes (p0.001); chronic obstructive pulmonary disease
(p0.002), Grace-Score (p0.002) intervention (p0.003), increased body mass index
(p0.018) and age (p0.042).
Conclusions: In our large data base of 1001 patients age was not the main predictor of
long-time mortality. Therefore advanced age should not be the main factor in decision
making for conservative or invasive treatment in elderly patients with ACS and an
invasive strategy should be offered also to elderly patients.
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Background: An emphasis on sensitivity in the diagnosis of ST-segment elevation
myocardial infarction necessitates a certain degree of ‘false positive’ diagnoses. Little is
known about the long-term outcomes of those ultimately found to lack a culprit coronary
artery occlusion despite a putative STEMI diagnosis.
Methods: We analyzed a registry of all STEMI diagnoses established in the Emergency
Department (ED) at two urban centers from 2008 to 2011. Subsequent death, ED visits,
hospitalizations, and cardiac procedures at our study centers following index hospitaliza-
tion were evaluated. Statistical analyses were performed using Student’s t tests and
regression analyses.
Results: During a median follow up of 20 months (IQR12.2-29.6 months), 13 of 153
‘false positive’ STEMI diagnoses died as compared to 32 of 248 ‘true positives’ (p 
0.091) (Figure 1). After adjusting for traditional risk factors, all-cause mortality was not
statistically different between ‘true’ and ‘false’ STEMI diagnoses (AOR 2.26, 95% CI
0.21-24.23, p0.499). However, false positive status was associated with a significantly
higher likelihood of a recurrent visit to the emergency department (AOR 2.73, 95% CI
1.24-6.02 p0.01), and an increased rate of re-hospitalization (1.04 additional hospital-
izations, 95% CI 0.21-1.86, p0.01) though they also had a trend towards fewer
subsequent myocardial infarctions (AOR 0.92, 95% CI 0.17 to 0.01, p0.07).
Conclusions: Patients with ‘false positive’ STEMI diagnoses have rates of long term
all-cause mortality comparable to a ‘true’ STEMIs population and have potentially greater
rates of recurrent resource utilization. Patients diagnosed with a putative STEMI but found
to lack a culprit coronary artery occlusion on angiography remain at great risk for
subsequent events and require further study.
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Background: The aim of this study was to investigate the effects of baseline anaemia on
the outcome of patients treated by primary percutaneous intervention (PPCI) for ST
elevation myocardial infarction.
Methods: We undertook a retrospective cohort study of 2418 STEMI patients treated
with PPCI between January 2004 and August 2010 at a single centre. We investigated the
outcome of patients with anaemia compared to patients with a normal haemoglobin level.
Anaemia was defined according to the WHO definition of haemoglobin (Hb) less than 12
g/dl for females and 13 g/dl for males. We also calculated hazard ratios (HRs) using a
stratified model according to haemoglobin level.
Results: 471 (19%) patients were anaemic at presentation. The anaemic cohort were
older (72.2 vs. 62.4, p0.0001), had higher incidence of diabetes (28% vs. 16%,
p0.0001), hypertension (57% vs. 43%, p0.01), hypercholesterolaemia (48% vs. 40%,
p0.007), previous PCI (15% vs. 9%, p0.0001), previous MI (23% vs. 12%, p0.002)
and cardiogenic shock (12% vs. 5%, P0.0001). Over a mean follow-up period of 3-years
there was significantly higher all cause mortality in the anaemic group compared to the
normal Hb group (20.4% vs. 13.5%, p0.0001). However, after adjustment for all
variables using multivariate analysis, anaemia (based on the WHO definitions) was not an
independent predictor of mortality or major adverse cardiac events (MACE) over the
follow-up period. However, when we used a stratified model by g/dL we found that in
men there was an increased risk of adverse outcome with low Hb. There appeared to be
a threshold value of haemoglobin (13 g/dL) associated with increased risk. Although a
similar trend was observed for women no significant difference was observed.
Conclusions: Patients with anaemia undergoing primary PCI are at higher risk of an
adverse outcome. Anaemia is a simple and powerful marker of poor prognosis. Although
after multivariate analysis, anaemia (based on WHO definitions) does not appear to be an
independent predictor of all-cause mortality or MACE after primary PCI, in men there
appears to be a threshold value of Hb, below which there is an associated increased risk.
TCT-506
Out-Of-Hours Outcomes in STEMI Patients Treated With Primary
Percutaneous Coronary Intervention
Krishnaraj Rathod1, Daniel Jones1, Vrijraj Rathod1, Sean Gallagher1, Ajay Jain1,
Anthony Mathur1, Andrew Wragg1, Charles Knight1
1Bartshealth NHS Trust, The London Chest Hospital, London, United Kingdom
Background: The aim of our study was to determine the short and long-term outcomes
between patients undergoing PPCI during ‘normal hours’ (i.e. In-hours) versus ‘out-of-
hours’. Our primary end point was mortality with a follow-up upto five years.
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